A
Angela Dispenzieri
Researcher at Mayo Clinic
Publications - 1212
Citations - 72269
Angela Dispenzieri is an academic researcher from Mayo Clinic. The author has contributed to research in topics: Multiple myeloma & Amyloidosis. The author has an hindex of 117, co-authored 1107 publications receiving 60367 citations. Previous affiliations of Angela Dispenzieri include University of Rochester & Kyungpook National University Hospital.
Papers
More filters
Journal ArticleDOI
Bone marrow amyloid: a comprehensive analysis of 1,469 samples, including amyloid type, clinical features, and morphologic distribution
April Chiu,Surendra Dasari,Paul J. Kurtin,Jason D. Theis,Julie A. Vrana,Angela Dispenzieri,Karen L. Rech,Linda N. Dao,Matthew T. Howard,Martha Grogan,Ellen D. McPhail +10 more
TL;DR: ATTR amyloid is common in bone marrow and its morphologic distribution overlaps with AL, and its pathognomonic features, including periosteal soft tissue and/or vascular involvement in ATTR, and variable anatomic compartment involvement in AL are found.
Journal ArticleDOI
The Natural History of Smoldering (Asymptomatic) Multiple Myeloma.
Robert A. Kyle,Ellen D. Remstein,Terry M. Therneau,Angela Dispenzieri,Paul J. Kurtin,Janice M. Hodnefield,Dirk R. Larson,Matt Plevak,L. Joseph Melton,S. Vincent Rajkumar +9 more
TL;DR: The medical records and bone marrows of all patients from Mayo Clinic seen within 30 days of recognition of an IgG or IgA M protein ≥ 3g/dL or a bone marrow containing ≥ 10% plasma cells from 1970 to 1995 were reviewed to allow for a minimum potential follow-up of 10 years.
Journal ArticleDOI
Cost Effectiveness Decision Tree Analysis of Early Versus Late Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma (MM) in the United States (US)
Shahrukh K. Hashmi,Chintan Pandya,Nandita Khera,Morie A. Gertz,Angela Dispenzieri,William J. Hogan,Mustaqeem A. Siddiqui,Katia Noyes,Shaji Kumar +8 more
Journal ArticleDOI
Daratumumab, Ixazomib, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma
Shaji Kumar,Prashant Kapoor,Betsy LaPlant,Liang Phuong-Dung,Eli Muchtar,Francis K. Buadi,Wilson I. Gonsalves,Gabriella C Malave,Alanna M. Vossen,David Dingli,Ronald S. Go,Rahma Warsame,Taxiarchis Kourelis,Yi L. Hwa,Amie Fonder,Miriam Hobbs,John A. Lust,Martha Q. Lacy,Angela Dispenzieri,Suzanne R. Hayman,Nelson Leung,S. Vincent Rajkumar,Morie A. Gertz +22 more
TL;DR: Dara-IRd is an active regimen in newly diagnosed MM, with high overall rates of response and deep responses that improved over time with therapy, and early discontinuation of dexamethasone does not appear to impact the depth, rate or kinetics of response.